Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aldagen, Inc. | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Aldagen, Inc.

Lyle A. Hohnke, Ph.D. has been appointed chief executive officer of Aldagen, Inc.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lyle A. Hohnke, Ph.D. has been appointed chief executive officer of Aldagen, Inc. Dr. Hohnke has more than 35 years of health care industry experience and has served on Aldagen’s board of directors since 2008. He succeeds Tom Amick.

“We appreciate the guidance Tom has given Aldagen over the years, and thank him for his many contributions that have brought the company to its current stage of development,” said Richard Kent, M.D., chairman of Aldagen. “Lyle’s involvement with the company as a board member, and his significant fundraising and operational experience make him a great addition to Aldagen’s executive management team.”

Dr. Hohnke was most recently a partner at Tullis Dickerson, a healthcare-focused venture capital fund. He has specific expertise in identifying and evaluating the commercial possibilities of new technologies, and in the technology transfer process. Prior to Tullis, Dr. Hohnke was a general partner of an Iowa-based venture capital fund, where he led a leveraged buyout of a division of Bayer A.G.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters